Cargando…

Dual inhibition of BRAF and mTOR in BRAF(V600E)-mutant pediatric, adolescent, and young adult brain tumors

Although BRAF inhibition has demonstrated activity in BRAF(V600)–mutated brain tumors, ultimately these cancers grow resistant to BRAF inhibitor monotherapy. Parallel activation of the phosphatidylinositol 3-kinase-mammalian target of rapamycin pathway has been implicated as a mechanism of primary a...

Descripción completa

Detalles Bibliográficos
Autores principales: Sen, Shiraj, Tanaka, Ryuma, Khatua, Soumen, Zaky, Wafik, Janku, Filip, Penas-Prado, Marta, Weathers, Shiao-Pei, Behrang, Amini, Roszik, Jason, Subbiah, Vivek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476413/
https://www.ncbi.nlm.nih.gov/pubmed/32843426
http://dx.doi.org/10.1101/mcs.a005041
_version_ 1783579696015867904
author Sen, Shiraj
Tanaka, Ryuma
Khatua, Soumen
Zaky, Wafik
Janku, Filip
Penas-Prado, Marta
Weathers, Shiao-Pei
Behrang, Amini
Roszik, Jason
Subbiah, Vivek
author_facet Sen, Shiraj
Tanaka, Ryuma
Khatua, Soumen
Zaky, Wafik
Janku, Filip
Penas-Prado, Marta
Weathers, Shiao-Pei
Behrang, Amini
Roszik, Jason
Subbiah, Vivek
author_sort Sen, Shiraj
collection PubMed
description Although BRAF inhibition has demonstrated activity in BRAF(V600)–mutated brain tumors, ultimately these cancers grow resistant to BRAF inhibitor monotherapy. Parallel activation of the phosphatidylinositol 3-kinase-mammalian target of rapamycin pathway has been implicated as a mechanism of primary and secondary resistance to BRAF inhibition. Moreover, it has been shown specifically that mTOR signaling activation occurs in BRAF-mutant brain tumors. We therefore conducted phase 1 trials combining vemurafenib with everolimus, enrolling five pediatric and young adults with BRAF(V600)-mutated brain tumors. None of the patients required treatment discontinuation as a result of adverse events. Overall, two patients (40%) had a partial response and one (20%) had 12 mo of stable disease as best response. Co-targeting BRAF and mTOR in molecularly selected brain cancers should be further investigated.
format Online
Article
Text
id pubmed-7476413
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cold Spring Harbor Laboratory Press
record_format MEDLINE/PubMed
spelling pubmed-74764132020-09-18 Dual inhibition of BRAF and mTOR in BRAF(V600E)-mutant pediatric, adolescent, and young adult brain tumors Sen, Shiraj Tanaka, Ryuma Khatua, Soumen Zaky, Wafik Janku, Filip Penas-Prado, Marta Weathers, Shiao-Pei Behrang, Amini Roszik, Jason Subbiah, Vivek Cold Spring Harb Mol Case Stud Research Report Although BRAF inhibition has demonstrated activity in BRAF(V600)–mutated brain tumors, ultimately these cancers grow resistant to BRAF inhibitor monotherapy. Parallel activation of the phosphatidylinositol 3-kinase-mammalian target of rapamycin pathway has been implicated as a mechanism of primary and secondary resistance to BRAF inhibition. Moreover, it has been shown specifically that mTOR signaling activation occurs in BRAF-mutant brain tumors. We therefore conducted phase 1 trials combining vemurafenib with everolimus, enrolling five pediatric and young adults with BRAF(V600)-mutated brain tumors. None of the patients required treatment discontinuation as a result of adverse events. Overall, two patients (40%) had a partial response and one (20%) had 12 mo of stable disease as best response. Co-targeting BRAF and mTOR in molecularly selected brain cancers should be further investigated. Cold Spring Harbor Laboratory Press 2020-08 /pmc/articles/PMC7476413/ /pubmed/32843426 http://dx.doi.org/10.1101/mcs.a005041 Text en © 2020 Sen et al.; Published by Cold Spring Harbor Laboratory Press http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/) , which permits reuse and redistribution, except for commercial purposes, provided that the original author and source are credited.
spellingShingle Research Report
Sen, Shiraj
Tanaka, Ryuma
Khatua, Soumen
Zaky, Wafik
Janku, Filip
Penas-Prado, Marta
Weathers, Shiao-Pei
Behrang, Amini
Roszik, Jason
Subbiah, Vivek
Dual inhibition of BRAF and mTOR in BRAF(V600E)-mutant pediatric, adolescent, and young adult brain tumors
title Dual inhibition of BRAF and mTOR in BRAF(V600E)-mutant pediatric, adolescent, and young adult brain tumors
title_full Dual inhibition of BRAF and mTOR in BRAF(V600E)-mutant pediatric, adolescent, and young adult brain tumors
title_fullStr Dual inhibition of BRAF and mTOR in BRAF(V600E)-mutant pediatric, adolescent, and young adult brain tumors
title_full_unstemmed Dual inhibition of BRAF and mTOR in BRAF(V600E)-mutant pediatric, adolescent, and young adult brain tumors
title_short Dual inhibition of BRAF and mTOR in BRAF(V600E)-mutant pediatric, adolescent, and young adult brain tumors
title_sort dual inhibition of braf and mtor in braf(v600e)-mutant pediatric, adolescent, and young adult brain tumors
topic Research Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476413/
https://www.ncbi.nlm.nih.gov/pubmed/32843426
http://dx.doi.org/10.1101/mcs.a005041
work_keys_str_mv AT senshiraj dualinhibitionofbrafandmtorinbrafv600emutantpediatricadolescentandyoungadultbraintumors
AT tanakaryuma dualinhibitionofbrafandmtorinbrafv600emutantpediatricadolescentandyoungadultbraintumors
AT khatuasoumen dualinhibitionofbrafandmtorinbrafv600emutantpediatricadolescentandyoungadultbraintumors
AT zakywafik dualinhibitionofbrafandmtorinbrafv600emutantpediatricadolescentandyoungadultbraintumors
AT jankufilip dualinhibitionofbrafandmtorinbrafv600emutantpediatricadolescentandyoungadultbraintumors
AT penaspradomarta dualinhibitionofbrafandmtorinbrafv600emutantpediatricadolescentandyoungadultbraintumors
AT weathersshiaopei dualinhibitionofbrafandmtorinbrafv600emutantpediatricadolescentandyoungadultbraintumors
AT behrangamini dualinhibitionofbrafandmtorinbrafv600emutantpediatricadolescentandyoungadultbraintumors
AT roszikjason dualinhibitionofbrafandmtorinbrafv600emutantpediatricadolescentandyoungadultbraintumors
AT subbiahvivek dualinhibitionofbrafandmtorinbrafv600emutantpediatricadolescentandyoungadultbraintumors